Peter Ordentlich

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia”.

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Nature(2023)10.1038/s41586-023-05812-3

N/A

5.2DataRank · unranked

480 citations

Ibrahim Aldoss, John F. Dipersio, Branko Cuglievan, Richard M. Stone, Martha Arellano +19 more

Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

Journal of Clinical Oncology(2022)10.1200/jco.22.00958

N/A

2.9DataRank · unranked

99 citations

Mukta Arora, Zachariah DeFilipp, Mohammad Abu Zaid, Antonio Di Stasi, Vedran Radojčić +16 more

Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3305

N/A

0.725DataRank · unranked

125 citations

Pasi A. Jänne, Mateusz Opyrchal, Navid Hafez, Luis E. Raez, Dmitry I. Gabrilovich +15 more

Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model

Haematologica(2023)10.3324/haematol.2022.281927

N/A

0DataRank · unranked

5 citations

Po Yee Mak, Wenjing Tao, Lauren B. Ostermann, Duncan H. Mak, Baozhen Ke +4 more